Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC)

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 33; no. 15_suppl; p. 7540
Main Authors O'Brien, Mary E.R., Kelly, Karen, Altorki, Nasser K., Eberhardt, Wilfried Ernst Erich, Spigel, David R., Crino, Lucio, Tsai, Chun-Ming, Kim, Joo-Hang, Cho, Eun Kyung, Hoffman, Philip C., Keshavjee, Shaf, Orlov, Sergey, Serwatowski, Piotr, Wang, Joe, Foley, Margaret A., Horan, Julie D., Shepherd, Frances A.
Format Journal Article
LanguageEnglish
Published 20.05.2015
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2015.33.15_suppl.7540